Previous 10 | Next 10 |
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q1 GAAP EPS of -$0.19 misses by $0.02 . Revenue of $4.9M (+53.1% Y/Y) misses by $0.89M . Shares -1.8% . Press Release More news on: Adamis Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, ,
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceutic...
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and alle...
Source: BigCharts Long-suffering shareholders have seemingly thrown in the towel on Adamis ( ADMP ) - again! When will they ever learn? Just over the past year, ADMP has fallen and rebounded many times (see my earlier article) . Interestingly, the stock penetrated a lower technical suppor...
Adamis Pharmaceuticals ( ADMP ) has reverted to its old ways of a mixed bag of information compiled over multiple press releases with little clarification from the CEO Dr. Dennis J. Carlo. The company finished 2018 with filing two NDAs and started 2019 with the launch of their flagship pro...
Adamis Pharmaceuticals (NASDAQ: ADMP ): FY GAAP EPS of -$1.00 misses by $0.11 . More news on: Adamis Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals,...
Adamis Pharmaceuticals (NASDAQ: ADMP ) +9.5% after-hours on news that the FDA accepted for review its New Drug Application for its higher dose naloxone injection product candidate to treat opioid overdoses. More news on: Adamis Pharmaceuticals Corporation, Healthcare stocks news, ...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate f...
Weight Watchers (NYSE: WTW ) -35% on Q4 earnings . More news on: Weight Watchers International, Inc., e.l.f. Beauty, Dycom Industries Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...